1. BCR–ABL1 B-ALLs feature DNA methylation and expression signatures centered aroundIL2RA(CD25).
BCR–ABL1 B-ALLs feature DNA methylation and expression signatures centered aroundIL2RA(CD25). Methylation signature (A) and expression signature (B) of BCR–ABL1-positive versus BCR–ABL1-negative B-ALLs. Each row represents one probeset and each column one patient. The color scale bars represent the methylation or expression levels. The probability of signatures to reclassify cases according to BCR–ABL1 status is shown on the top. The actual case labels: red, BCR–ABL1-positive; blue, BCR–ABL1-negative. The numbers of correctly classified and misclassified cases are given below the heatmap. C, the difference of mean methylation or expression values in BCR–ABL1-positive versus -negative B-ALL is depicted by the color scale on the 11 core genes overlapping between methylation and expression signatures. D, the gene network most highly enriched by methylation and expression signatures in BCR–ABL1 B-ALLs is centered around IL2RA (CD25). E, the degree of IL2RA hypomethylation and expression from E2993 cases and from an independent cohort of 132 patients with St. Jude B-ALLs (4, 39) in BCR–ABL1-positive versus BCR–ABL1-negative and versus normal pre-B cells. MassArray (F) and qPCR (G) validation for IL2RA (CD25). The color key represents % methylation of each promoter CpG (rows). Columns represent individual cases. Location of HELP probesets and EpiTyper primers on IL2RA are shown (UCSC genome browser hg19). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Huimin Geng et al. Cancer Discovery 2012;2:
©2012 by American Association for Cancer Research